Related Experiment Videos
The current status of thrombolytic therapy
1Flinders Medical Centre, Adelaide, SA.
Insights
Fibrinolytic therapy significantly lowers mortality in acute myocardial infarction (AMI). Optimal patient selection and individualized treatment regimens, considering risks and costs, are crucial for effective care.
Area of Science:
- Cardiology
- Emergency Medicine
- Pharmacology
Background:
- Fibrinolytic therapy is a cornerstone in reducing mortality for acute myocardial infarction (AMI).
- Effective patient selection and appropriate treatment protocols are vital for maximizing benefits and minimizing risks.
- Understanding contraindications and risk factors is essential for safe and effective fibrinolysis.
Purpose of the Study:
- To review patient selection criteria for fibrinolytic therapy in acute myocardial infarction.
- To discuss contraindications and factors influencing treatment regimen choice.
- To highlight the importance of individualized therapy based on patient-specific risks.
Main Methods:
- Review of current guidelines and clinical trial data (e.g., COBALT trial) on fibrinolytic therapy for AMI.
- Analysis of patient characteristics, including symptom onset, ECG findings, and contraindications.
- Comparison of different fibrinolytic regimens and adjunctive therapies like heparin.
Main Results:
- Fibrinolytic therapy requires patients to present within 12 hours of ischemic symptoms with ECG changes and no contraindications (e.g., recent stroke, intracranial tumor, major bleeding risk).
- Age and hypertension are not absolute contraindications but may necessitate regimen modification.
- The COBALT trial indicated the accelerated weight-related tissue plasminogen activator (t-PA) regimen is favorable, though equivalent to double bolus t-PA in patients under 75.
Conclusions:
- Individualized treatment selection for acute myocardial infarction is now recommended over a one-size-fits-all approach.
- Treatment choices should be based on a comprehensive assessment of cardiac risk, stroke risk, bleeding risk, and cost.
- Optimizing fibrinolytic therapy requires careful consideration of patient-specific factors and evolving clinical evidence.
Abstract:
Fibrinolytic therapy substantially reduces mortality from acute myocardial infarction. Patient selection is, however, important. The patient must present within 12 hours of the onset of ischaemic symptoms, have definite ECG changes of ST elevation or left bundle branch block and no contraindications. The major contraindications are those for risk of an intracerebral bleed, recent stroke, intracranial tumour or risk of a major systemic bleed. Age and hypertension are not contraindications but may modify the regimen used. Heparin is required with recombinant tissue plasminogen activator but is optional with streptokinase. The recent COBALT trial suggests that the accelerated weight related t-PA regimen given over 90 minutes is more satisfactory than double bolus t-PA. However, in patients under 75 years of age, the two regimens were equivalent. For patients suffering acute myocardial infarction, practitioners should now individualise choice of therapy, rather than give the same cocktail to all patients. The choice of regimen will depend on the cardiac risk, the stroke risk, the bleeding risk and the cost.